

Remarks

Applicants hereby elect Group I, with traverse only to the extent that Claim 12 appears to be inadvertently omitted from the present restriction. Applicants suggest that Claim 12 may properly be prosecuted with the examination of Group I, as a method of use for the compounds of Group I. Applicants respectfully request reconsideration of this matter.

Applicants elect the species of Example 7, that is, 8-Ethanesulfonyl-5-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-5H-6-oxa-chrysen-2-ol to assist the Examiner with searching and examination of the claimed invention. Applicants reserve the right to file one or more divisional applications to claim any non-elected subject matter.

Applicants do not wish to amend inventorship in light of the election of Group I.

Applicants request that the examiner contact the undersigned attorney regarding any matters relating to this application, which may further the prosecution of the application.

Respectfully submitted,

/MaCharri Vorndran-Jones/

MaCharri Vorndran-Jones  
Attorney for Applicant(s)  
Registration No. 36,711  
Phone: 317-276-1665

Eli Lilly and Company  
Patent Division  
P.O. Box 6288  
Indianapolis, Indiana 46206-6288

June 11, 2009